Diabetes may lead to a loss of kidney function. The FAME 2 Kidney trial is testing if a once daily blood fat lowering tablet can slow kidney disease progression in adults with type 2 diabetes.
Who can participate?
You may be eligible for this trial if you:
- are aged over 18 years
- have been diagnosed with type 2 diabetes and moderate kidney damage.
Where is the FAME 2 Kidney trial being conducted in Australia?
The Baker Heart and Diabetes Institute is one of 7 sites around Australia that are participating in the FAME 2 Kidney trial. Other sites are in Sydney, Melbourne, Perth and Canberra.
What is involved?
If you are interested in participating, you will need to complete a screening visit to determine if you are eligible for this trial. This appointment will occur at the FAME 2 Kidney participating site or hospital/clinic that you usually attend for your diabetes care.
If you take part in this project, you will likely be in it for about 3 1/2 years and involve a minimum of 11 clinic visits. The clinic visits are ideally planned to occur at the same time as your regular visits to your diabetes clinic or doctor. You will be asked to take one tablet daily and we will closely monitor the health of your kidneys whilst you are participating in the trial.
By taking part, you will help the researchers and other doctors and nurses around the world understand more about kidney damage with type 2 diabetes and specifically if a once daily fenofibrate tablet can slow kidney damage and other related complications. This knowledge may help many people in the future.